Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2016 1
2017 1
2018 1
2019 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.
Brown LJ, da Silva IP, Moujaber T, Gao B, Hui R, Gurney H, Carlino M, Nagrial A. Brown LJ, et al. Among authors: moujaber t. Cancer Med. 2023 Mar;12(6):6788-6801. doi: 10.1002/cam4.5468. Epub 2022 Nov 20. Cancer Med. 2023. PMID: 36404632 Free PMC article.
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.
Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A; Australian Ovarian Cancer Study Group. Etemadmoghadam D, et al. Among authors: moujaber t. Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23. Cancer Res. 2017. PMID: 28646021
BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.
Moujaber T, Etemadmoghadam D, Kennedy CJ, Chiew YE, Balleine RL, Saunders C, Wain GV, Gao B, Hogg R, Srirangan S, Kan C, Fereday S, Traficante N; Australian Ovarian Cancer Study; Patch AM, Pearson JV, Waddell N, Grimmond SM, Dobrovic A, Bowtell DDL, Harnett PR, deFazio A. Moujaber T, et al. JCO Precis Oncol. 2018 Nov;2:1-14. doi: 10.1200/PO.17.00221. JCO Precis Oncol. 2018. PMID: 35135122
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M, O'Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, Grant P, Davis A, Sykes P, Mileshkin L, Moujaber T, Kennedy CJ, deFazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M. Tang M, et al. Among authors: moujaber t. Gynecol Oncol. 2019 Sep;154(3):531-538. doi: 10.1016/j.ygyno.2019.06.011. Epub 2019 Jun 18. Gynecol Oncol. 2019. PMID: 31227223 Clinical Trial.